|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/23/20 AC Immune SA 6-K 3/23/20 3:65K Davis Polk & … LLP 01/FA |
Document/Exhibit Description Pages Size 1: 6-K Current Report by a Foreign Issuer HTML 12K 2: EX-10.1 Material Contract HTML 15K 3: EX-99.1 Miscellaneous Exhibit HTML 17K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2020
Commission File Number: 001-37891
AC IMMUNE SA
(Exact name of registrant as specified in its charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F |
X |
Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
| Yes | No |
X |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Yes | No |
X |
C:
On March 20, 2020, AC Immune SA (the “Company”) and Eli Lilly and Company (“Lilly”) entered into a second amendment (the “Second Amendment”) to their license and collaboration agreement dated as of December 11, 2018, as amended by the first amendment to such agreement dated as of September 19, 2019 (“License Agreement”) relating to the research and development of Tau Morphomer small molecules for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Pursuant to the Second Amendment, the parties have replaced the 30 million Swiss Francs milestone due on or before March 31, 2020 with two milestone payments. Specifically, Lilly will be required to pay to the Company 10 million Swiss Francs on or before March 31, 2020 and 60 million Swiss Francs within 60 days after the first patient is dosed in a first Phase 2 clinical trial of any licensed product in the United States or European Union.
C:
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AC IMMUNE SA | |||
| By: | /s/ Andrea Pfeifer | ||
| Name: | Andrea Pfeifer | ||
| Title: | Chief Executive Officer | ||
| By: | /s/ Joerg Hornstein | ||||
| Name: | Joerg Hornstein | ||||
| Title: | Chief Financial Officer | ||||
| Date: | March 23, 2020 | ||||
C:
Exhibit Index
|
Exhibit Number |
Description |
| 10.1* | Second Amendment to License Agreement between AC Immune SA and Eli Lilly and Company, dated March 20, 2020 |
| 99.1* | Press Release dated March 23, 2020 |
| * | Filed herewith |
C:
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 3/31/20 | None on these Dates | |||
| Filed on / For Period end: | 3/23/20 | |||
| 3/20/20 | ||||
| 9/19/19 | ||||
| 12/11/18 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/24 AC Immune SA 20-F 12/31/23 125:20M Toppan Merrill Bridge/FA 3/16/23 AC Immune SA 20-F 12/31/22 121:20M Toppan Merrill Bridge/FA 3/22/22 AC Immune SA 20-F 12/31/21 119:18M Broadridge Fin’l So… Inc 3/23/21 AC Immune SA 20-F 12/31/20 110:14M Davis Polk & … LLP 01/FA |